AlphAIAlphAI — Financial news for AI agents
fool.comSEP 82 min read$TDOC

2 Beaten-Down Stocks to Avoid Right Now

Teladoc Health (TDOC) and Recursion Pharmaceuticals (RXRX) face significant challenges. Teladoc's revenue declined 4% YoY to $606.9M, with BetterHelp's revenue and users dropping 12% and 11% YoY, respectively. Recursion, an AI-driven biotech, lacks approved products and has seen its stock fall 21% over the past year. Both companies show dim prospects, according to the analysis.

Original reporting
fool.com
Published Sep 8, 2026, 6:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 6:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
2 Beaten-Down Stocks to Avoid Right Now — source image
Source · fool.com
Decision brief

The 30-second read

$TDOCBearishLow
01

Why it matters

Both companies face structural headwinds; the piece offers no new data beyond existing earnings releases.

02

Market read

Limited trading relevance; primarily a cautionary note rather than a catalyst‑driven move.

03

What to watch

Potential future insurance contracts for Teladoc and undisclosed AI breakthroughs at Recursion could alter outlook.

Relevance 4/10Novelty 2/10Timing: post‑Q2 earnings recap

Background

The article is a recommendation to avoid two heavily beaten‑down healthcare stocks, summarizing recent quarterly performance and strategic challenges.

Company-level read

Ticker impact

$TDOCBearishMedium confidence
Context

Teladoc Health reported a Q2 revenue decline of 4% YoY and a wider loss per share, reinforcing its dim outlook.

Expected impact

Neutral to slightly down as investors may further discount the stock.

Evidence & confidence

The article recaps already‑released earnings without new information, limiting actionable insight.

$RXRXBearishMedium confidence
Context

Recursion Pharmaceuticals disclosed no approved products and no Phase 3 trials, highlighting continued risk after a 21% stock decline over the past year.

Expected impact

Likely flat to down as investors remain skeptical.

Evidence & confidence

The piece repeats known status of the firm without fresh data, offering limited trading impetus.

Market effects

Sector

Reinforces bearish sentiment in the broader telehealth and AI‑biotech subsectors.

Regional

Minimal; effects confined to U.S. healthcare equities.

Global

Limited to investors tracking health‑tech stocks.

Counterpoint

What could challenge this read

Some investors may view the low valuations as a long‑term entry point if turnaround initiatives succeed.

Key entities

  • company
    Teladoc Health

    Telemedicine provider with declining Q2 results.

  • company
    Recursion Pharmaceuticals

    AI‑focused biotech lacking approved products.

Read at source← All news

Related articles

OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal And ARK Buying Fuel AI-Drug Hype

Recursion Pharmaceuticals (RXRX) stock rose 4.26% on optimism over AI-driven drug advances. The company reported positive Phase 1b/2 trial results for REC-4881 and early Phase 1 data for REC-1245. Sanofi optioned a candidate, triggering a $10M milestone. RXRX raised $200M, extending its cash runway. The stock has high volatility, trading at a 43x P/S ratio with negative margins.

timothysykes.com3 min
OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Fuel AI Biotech Story

Recursion Pharmaceuticals Inc. (RXRX) stock rose 3.85% on AI-driven drug discovery progress and institutional buying. The company reported positive Phase 1b/2 data for REC-4881 and REC-1245, and Sanofi exercised an option on an inflammatory candidate, triggering a $10M milestone. RXRX raised $200M in a follow-on offering, and ARK Investment Management has been accumulating shares. The company has no near-term profits but has a strong cash position and strategic partnerships.

timothysykes.com3 min
OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Ignite Momentum

Recursion Pharmaceuticals (RXRX) stock rose 3.85% on news of a Sanofi partnership and ARK Investment's purchases. The company reported positive clinical data for REC-4881 and REC-1245, and raised $200M in equity. RXRX has a strong cash position and a runway into 2029, but remains unprofitable with negative margins.

stockstotrade.com3 min
OCT 16
$RXRXHighAI 9/10

Key facts: RXRX REC-4881 strong efficacy, clean safety; Runway into 2029

Recursion (RXRX) reported positive results from its Phase 1b/2 trial of REC-4881, showing an 87% mean reduction in GI polyp burden and a 92% reduction in upper GI. The drug demonstrated a favorable safety profile, with no treatment-related adverse events above Grade 3. The company plans a registrational trial in H2 2027, pending FDA discussions. Recursion had $561M in cash as of Sept 30, 2026, and expects $200M from a recent offering, extending its runway into 2029.

tradingview.com1 min
OCT 15
$RXRXMed

Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar

Recursion Pharmaceuticals (RXRX) shares surged 17.9% after Sanofi initiated development of drug molecules, triggering a $10M milestone payment, totaling $144M received. RXRX may earn over $300M more in milestones and royalties if approved. The collaboration, started in 2022, focuses on AI-enabled small molecule therapies in immunology and oncology. Hedge fund holdings in RXRX increased 16% QoQ to $287.9M, despite a drop in the number of funds invested.

insidermonkey.com2 min